Clinical and Research Solutions to Manage Obstructive Sleep Apnea: A Review

Mohamad Sawan, Fieee, Frsc, Fcae, Feic, O.q., Fen Xia, Mohamad SawanSensors 2021 · DOI

TL;DR

This review paper provides a comprehensive overview of current and emerging clinical and research solutions for managing Obstructive Sleep Apnea (OSA). It analyzes various treatment methodologies, their success rates, limitations, and economic burdens, aiming to guide physicians and patients in selecting optimal interventions.

What Problem Does This Paper Address?

Obstructive Sleep Apnea (OSA) is a prevalent and serious sleep disorder affecting millions worldwide, leading to significant health risks like stroke and sudden death. While various treatments exist, there's a need for a clear, evidence-based comparison to help clinicians and patients navigate the complex landscape of diagnostic and therapeutic options. The paper addresses the challenge of choosing the most suitable treatment based on individual patient characteristics, OSA severity, and treatment efficacy, while also highlighting research gaps and future directions.

Methods

This review paper employs a comprehensive literature search strategy, utilizing databases such as Google Scholar, PubMed, Web of Science, and IEEE Xplore. The search focused on publications from 2000 to 2021, prioritizing randomized controlled trials, reviews, systematic reviews, meta-analyses, and clinical trial journals written in English. The authors specifically focused on contributions published within the last five years to ensure the inclusion of the most recent advancements. The paper analyzes the methodologies of diagnostic and treatment methods, their success rates, and the associated economic burden.

Datasets

Not discussed in the paper. This is a review paper, not an empirical study with new datasets.

Key Insights and Ideas

  • OSA is a complex, multi-faceted disease: Its etiology is complex, and no single treatment can cure it, necessitating a multidisciplinary approach.
  • CPAP remains the gold standard but faces adherence challenges: While effective, nearly 50% of patients struggle with long-term CPAP use, driving the need for alternatives.
  • Oral Appliances (OAs) offer a viable alternative: They are more accepted by patients and show comparable effectiveness to CPAP for non-severe OSA, with success rates linked to mandibular advancement distance.
  • Weight loss is crucial, especially for obese patients: A 7-10% weight loss can significantly improve OSA severity, with bariatric surgery showing promising results.
  • Surgical interventions are reserved for severe cases or CPAP failures: Procedures like UPPP and MMA can be effective but come with significant risks and limitations.
  • Neural electrical stimulation (HGNS) is a promising emerging therapy: It offers a less invasive approach with high cure rates and potential for future miniaturization and smart integration.
  • Transcutaneous Electrical Stimulation (TES) is a potential non-invasive option: While showing less efficiency than HGNS in some studies, it's more cost-effective and has minimal adverse events, making it a candidate for future investigation.
  • Treatment success is highly variable: Factors like patient adherence, BMI, severity of OSA, and follow-up duration significantly influence outcomes.

Key Results

  • CPAP: Shows a high effective outcome with a 59.3% treatment success rate in adults.
  • Oral Appliances (OAs): 68% of patients with OSA experienced treatment success in a 4-year follow-up.
  • Weight Loss: A 27% decrease in OSA prevalence was observed after bariatric surgery. Minimal 7-10% weight loss is recommended for significant improvement.
  • UPPP + TE (Tonsillectomy): Showed a higher treatment success rate of 64.5% at 3 months compared to UPPP alone.
  • Maxillomandibular Advancement (MMA): Demonstrated a mean AHI reduction from 36.7 to 4.7 in successful cases over a 12.5 ± 3.5-year follow-up, with a 27.6% success rate.
  • Hypoglossal Nerve Stimulation (HGNS): Demonstrates a high cure rate of 76% and a significant mean AHI reduction of 24.2 after 12 months.
  • Transcutaneous Electrical Stimulation (TES): Reduced AHI by 9.1 in a randomized trial, showing less efficiency than HGNS but being more cost-effective.

Limitations and Future Work

The authors acknowledge several limitations in their review, including the scarcity of studies directly comparing OSA treatments and the lack of uniformity in study designs, screening criteria, demographic structures, sample sizes, and follow-up times. This makes direct comparisons challenging.

Future research directions suggested include:

  • Developing comprehensive guidelines: Establishing clear criteria for specific screening and cure rates to guide treatment selection.
  • Extending treatment comparisons: Including factors beyond AHI reduction, such as operational complexity, cost, treatment time, and effects on physical function, quality of life, and neurocognition.
  • Increasing sample sizes: Ensuring sufficient sample sizes to mitigate the influence of demographic variations.
  • Further investigation of HGNS: With advancements in implantable medical devices, HGNS is expected to become smarter and more efficient.
  • Clinical investigation of TES: TES should be further explored as a potential non-invasive alternative due to its high tolerance and cost-effectiveness.
  • Multidisciplinary and integrated approach: Achieving efficient OSA therapeutic success will likely require a collaborative effort involving various medical specialties.

Summary updated

BibTeX
@article{oq2021clinical,
  author = {Mohamad Sawan, FIEEE, FRSC, FCAE, FEIC, O.Q. and Fen Xia and Mohamad Sawan},
  title = {{Clinical and Research Solutions to Manage Obstructive Sleep Apnea: A Review}},
  journal = {Sensors},
  year = {2021},
  doi = {10.3390/s21051784},
}
Figure